EFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
- Authors: Vakhlyarskaya S.S.1, Kondratenko I.V.1, Bologov A.A.1, Vakhlyarskaya SS1, Kondratenko IV1, Bologov AA1
-
Affiliations:
- Issue: No 6 (2012)
- Pages: 66-70
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279460
- ID: 279460
Cite item
Full Text
Abstract
The study including 30 children has evaluated the efficacy and safety of use of tumor necrosis factor α blocker adalimumab (Humira ®, Abbott Laboratories Ltd, UK) for the treatment of patients with different variants of juvenile rheumatoid arthritis (JRA). The results confirm the efficacy and safety of adalimumab in the treatment of various forms of JRA. It was concluded that early administration of adalimumab allows to achieve the better control of disease activity, avoid the complications of glucocorticosteroid therapy and the formation of steroiddependence in JRA
About the authors
Svetlana Sergeevna Vakhlyarskaya
Irina Vadimovna Kondratenko
Andrey Anatol'evich Bologov
S S Vakhlyarskaya
I V Kondratenko
A A Bologov
References
- Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti'tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate the ARMADA trial [published erratum appears in Arthritis Rheum 2003,48 855]. Arthritis Rheum 2003;48:35-45.
- Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
- Hoff M, Kvien T, Kaelvesten J, et al. Anti-TNE treatment with adalimumab reduces hand bone loss in early rheumatoid arthritis: Explorative analysis from the PREMIER study. Arthritis Rheum 2007;56:152-53.
- Furst DE, Schiff MN, Fleischman RM, et al. Adalimumab, a fulle human anti-TNF-α antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis; results of STAR (safety trial of adalimumab in rheumatoid irthritis). J Rheumatol 2003;30:2563-71.
- Mease PG, Gladman DD, Richlin CT, et al. Adalimumab for the treatment of patiants with moderately to severely active psoriatic arthritis: results of double-blind, randomized, placebo-control trial. Arthritis Rheum 2005;52:3279-89.
- Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65:753-59.
- Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumour necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebocontrolled, 52 weeks trial. Arthritis Rheum 2004;50:1400-11.
- Daniel J Lovell, M.D., M.P.H., Nicolino Ruperto, M.D., M.P.H., Steven Goodman, M.D. Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. N Engl J Med 2008;359:810-20.
- Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in the treat' ment of Juvenile Idiopathic Arthritis associated Uveitis - A Pilot Study. Abstract presented at: 8th Annual European League Against Rheumatism (EULAR 2007); June 13-16, 2007; Barcelona, Spain. Abstract THU0483.
- Sfriso P, Ravaioli F. Adalimumab in Juvenile Rheumatoid Arthritis. N Engl J Med 2008;359:2495-97.
- Taddio A, Marchetti F. Adalimumab in Juvenile Rheumatoid Arthritis. N Engl J Med 2008;359:2495-97.
- de Vries MK, van der Horst-Bruinsma IE, Wolbink GJ. Adalimumab in Juvenile Rheumatoid Arthritis N Engl J Med 2008;359:2496-97.
- Katsicas MM, Russo RAG. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol 2009;28:985-8.
- Papagoras C, Voulgari PV, Drosos AA. Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatology: Research and Reviews 2009;1:51-68.
Supplementary files
